ADHD Meds Offer Benefits Far Beyond Core Symptom Relief
Attention-deficit/hyperactivity disorder (ADHD) medications appeared to reduce the risk for suicide, drug misuse, transport incidents, and criminal activity,…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease Â
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…